- Home
- CREX vs ESLA Comparison
CREX vs ESLA Comparison
Compare CREX & ESLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CREX | ESLA |
|---|---|---|
| Founded | N/A | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.7M | 32.0M |
| IPO Year | 2015 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CREX | ESLA |
|---|---|---|
| Price | $2.64 | $0.53 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 23.8K | ★ 35.2K |
| Earning Date | 04-14-2026 | 05-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $18,437,000.00 | N/A |
| Revenue This Year | $81.98 | N/A |
| Revenue Next Year | $14.82 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 5.61 | N/A |
| 52 Week Low | $2.22 | $0.51 |
| 52 Week High | $4.42 | $3.15 |
Technical Indicators
Market Signals| Indicator | CREX | ESLA |
|---|---|---|
| Relative Strength Index (RSI) | 40.16 | 27.59 |
| Support Level | N/A | N/A |
| Resistance Level | $3.74 | $0.85 |
| Average True Range (ATR) | 0.22 | 0.08 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 9.37 | 5.75 |
Price Performance
Historical ComparisonAbout CREX Creative Realities Inc.
Creative Realities Inc, along with its subsidiaries, is engaged in providing digital marketing technology & solutions to world-wide retail companies, luxury and other individual retail brands, advertising networks, outdoor clients, enterprises, and other organizations. The company operates in one reportable segment, marketing technology solutions. It offers solutions related to digital merchandising systems, omnichannel customer engagement systems, interactive digital shopping assistants, advisors and kiosks, and high-end audio-visual networks, along with marketing technologies such as mobile, social media, point-of-sale transactions, beaconing, and web-based media. Geographically, the company generates maximum revenue from the United States, and the rest from Canada.
About ESLA Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors.